A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).

Trial Details

NCT ID
NCT06515613
Phase
PHASE1
Sponsor
Context Therapeutics Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • CTIM-76
Locations (sample)
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Denver, Colorado, United States|39.73915,-104.9847
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Participants with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer.
  • Participants with measurable disease per RECIST 1.1.
  • ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks.
  • Participants with adequate organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →